# Clinical trial patients

Type: group

Source: GetYourBrief — https://getyourbrief.com/entity/clinical-trial-patients
Canonical HTML page: https://getyourbrief.com/entity/clinical-trial-patients

## Timeline

- **2026-06-15**: Public Disclosure — Novo Nordisk publishes incident notice confirming unauthorized access and data theft, updating it in stages as investigation progressed.

## Recent coverage (3 stories, network-wide)

### 2 Groups Hit: Novo Nordisk Breach Exposes Clinical Trial Data and Provider PII
2026-06-16 01:40:18 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2

The theft of pseudonymized patient data—including biomarkers and lifestyle factors—threatens clinical trial integrity, while exposed provider identities create direct phishing risks. Healthcare leaders must reassess data governance in digital trials.
Full story: https://gethealthbrief.com/story/novo-nordisk-health-data-breach-implications

### Pharma Under Siege: 2 Data Types Stolen in Novo Nordisk Stealth Attack
2026-06-16 01:40:11 · Sector: cyber · Sentiment: Negative · Impact: 7/10 · Sources: 2

Novo Nordisk's breach reveals a stealthy exfiltration operation targeting high-value clinical and provider data, with no ransomware. The incident spotlights the pharmaceutical sector's expanding attack surface.
Full story: https://getcyberbrief.com/story/novo-nordisk-cyber-breach-attack-analysis

### Blockbuster Trial Data Exposed: 2 Affected Groups in Novo Nordisk Espionage
2026-06-16 01:40:04 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2

The biopharma sector faces a new espionage threat as attackers steal detailed clinical trial data from Novo Nordisk. Competitors could reverse-engineer GLP-1 trial endpoints and patient responder profiles.
Full story: https://getbiobrief.com/story/novo-nordisk-bio-data-breach-competitive-intelligence

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.